Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


Standard therapy for multiple myeloma (MM) usually includes an autologous bone marrow stem cell transplant - a procedure where the patient is treated with high dose chemotherapy and then their own (autologous) stem cells are transplanted back into their body. Patients with multiple myeloma and high risk genes, always relapse after an autologous transplant and often die within two years from the time of their transplant. A different type of transplant allogeneic) using donor cells, may work better for high-risk Multiple Myeloma, because the donor cells may help kill the lymphoid cancer cells. This study will investigate if a matched donor stem cell transplant using a newer, reduced toxicity, chemotherapy (Flu-Bu4) is a feasible option for patients with high risk, Multiple Myeloma.


Inclusion Criteria: - Biologic high risk Multiple Myeloma: - Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P- by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics; Hypodiploidy by conventional cytogenetics. - Relapsed or persistent multiple myeloma after ASCT. - Persistent multiple myeloma, regardless of previous therapies. - Plasma cell leukemia, regardless of previous therapies. - Age up to 70 years old (less than 71 years old at the date of transplant admission). - Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission - Patients with non-secretory and oligosecretory disease are eligible if they meet certain criteria within 2 weeks prior to the transplant. - Specific renal, liver, cardiac, and pulmonary function requirements(all must be met within 30 days of transplant admission) Exclusion Criteria: - Persistent invasive infections, not controlled by antimicrobials. - HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity. - Uncontrolled medical or psychiatric disorder. - No response or progressive disease at the time of transplantation. - Pregnancy



Primary Contact:

Principal Investigator
Attaphol Pawarode, MD
University of Michigan Dept. of Internal Medicine

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.